Despite the absence of mutations in the DNA repair machinery in myeloid malignancies, the advent of high-throughput sequencing and discovery of splicing and epigenetics defects in chronic myelomonocytic leukaemia (CMML) prompted us to revisit a pathogenic role for genes involved in DNA damage response. We screened for misregulated DNA repair genes by enhanced RNA-sequencing on bone marrow from a discovery cohort of 27 CMML patients and 9 controls. We validated 4 differentially expressed candidates in CMML CD34 + bone marrow selected cells and in an independent cohort of 74 CMML patients, mutationally contextualized by targeted sequencing, and assessed their transcriptional behavior in 70 myelodysplastic syndrome, 66 acute myeloid leukaemia and 25 chronic myeloid leukaemia cases. We found BAP1 and PARP1 down-regulation to be specific to CMML compared with other related disorders. Chromatin-regulator mutated cases showed decreased BAP1 dosage. We validated a significant over-expression of the double strand break-fidelity genes CDKN1A and ERCC1, independent of promoter methylation and associated with chemorefractoriness. In addition, patients bearing mutations in the splicing component SRSF2 displayed numerous aberrant splicing events in DNA repair genes, with a quantitative predominance in the single strand break pathway. Our results highlight potential targets in this disease, which currently has few therapeutic options.
The lack of recurrent, pathogenic somatic mutations in DNA repair mechanism components in myeloid malignancy has diverted attention away from interest in this pathway (Yoshida et al, 2011; Huang et al, 2015; Papaemmanuil et al, 2016) . However, recent studies have revealed the need for a finetuned equilibrium in stimulating DNA repair machinery that can prevent mutations, but which can also preclude the extinction of malignant blood cells by therapeutic agents (Tong et al, 2016) . Splicing factor and microsatellite anomalies disrupting genomic integrity maintenance and the biological rationale for combining polymerase inhibitors and demethylating agents are both recent findings that cause convergence between myeloid cancer and DNA repair (Gaymes et al, 2013; Dolatshad et al, 2015; Muvarak et al, 2016; Pederiva et al, 2016) .
The main goals of this study were: (i) to screen, by means of global and massive sequencing, for anomalies in the transcriptome of genes involved in the DNA repair machinery in patients with CMML, identifying targetable candidates; (ii) to validate their misregulation in an independent large CMML cohort, establishing their genomic and clinical context; and (iii) to assess potential neoplasm-specificity by determining how those candidates behave through the spectrum of myeloid malignancies.
Material and methods

Patients and samples
Bone marrow (BM) aspirates were collected during the diagnostic workup from 259 patients presenting to University Hospitals from Salamanca and Badalona (27 CMML discovery cohort cases) and to University Hospitals from Murcia [validation cohort of 74 CMML cases; and 70 MDS, 53 AML and 25 chronic myeloid leukaemia (CML) patients]. Diagnoses were made according to 2008 and 2016 World Health Organization classification (Vardiman et al, 2009; Arber et al, 2016) . In each case, informed consent was obtained in accordance with protocols approved by each centre 0 s Institutional Review Board and with the Declaration of Helsinki.
RNA-sequencing (RNA-Seq)
RNA extracted from BM samples obtained from 27 CMML patients and 9 healthy controls was used for deep RNA-Seq (mean 106 million reads per sample) on a HiSeq4000 sequencer (Illumina, San Diego, CA, USA). In five patients treated with azacitidine, a second BM sample at day +28 after 3 cycles of azacitidine was also sequenced. We used LIMMA package or empirical analysis of digital gene expression data in R (edgeR) (both available at: www.bioc onductor.org) to identify differential expression. Alternative 3 0 and 5 0 splice sites, skipped exons, mutually exclusive exons and retained introns were quantified using rMATS with the assembly produced from STAR (both available at: http://rnaseq-mats.sourceforge.net/) (Shen et al, 2014) . The default parameters were used for the comparison of the samples.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR), CD34 + cells isolation, and flow cytometry Differentially expressed genes (DEGs) results were validated by using TaqMan gene expression assays with probes from Thermo Fisher Scientific, Waltham, MA (Table SI). CD34  + cells were enriched from thawed BM using magnetic microbeads and an autoMACS â Pro Separator (Miltenyi Biotec, BergischGladbach, Germany). The granulomonocytic compartment was quantified in the discovery cohort using CD11b-fluorescein isothicyanate (FITC), CD13-phycoerythrin (PE), CD45-peridinin-chlorophyll (PerCP), and CD34-allophycocyanin (APC) performed on a FACSCanto II (Becton-Dickinson, San Jose, CA, USA).
DNA methylation analysis by pyrosequencing
Primer sequences are listed in Table SII . Bisulphite conversion of 500 ng of each DNA sample was performed with the EZ DNA Methylation-Gold Kit (Zymo Research, Milan Italy).
DNA targeted sequencing
We designed a TruSeq Custom Amplicon panel (Illumina, Inc. San Diego, CA, USA) including 18 genes recurrently mutated in CMML (Table SIII) . Sequencing was performed with MiSeq v2.2 chemistry, and a mean depth of 982 reads/ base was obtained.
Statistics
Analysis was performed using Student-t and Mann-Whitney-U test. The Kaplan-Meier method was used for survival outcomes. Significance was determined at a two-sided alpha level of 0Á05, except for P values in multiple comparisons, for which Bonferroni correction was applied (SPSS version 21.0; IBM SPSS Statistics, IBM Corporation, Armonk, NY, USA). Additional details on control samples, techniques and open databases are provided in Data S1.
Results
Global DNA repair genes expression in CMML: RNASeq
To investigate detailed gene expression signatures for the genes involved in DNA repair pathways we performed RNASeq on bone marrow in a discovery cohort of 27 CMML cases and 9 healthy controls. Donors (mean, 65 years of age.) were selected to match the advanced age of CMML patients. Main baseline patients' characteristics depicted in Table I . Of A. M. Hurtado et al the 204 genes considered in this analysis, the expression of 30 genes was significantly different between the two groups, with 8 genes up-regulated and 22 genes down-regulated in CMML patients ( Figure S1 , upper panel, and Table SIV) .
Defects in genes predominantly unique to a single strand break (SSB) repair pathway included: NEIL1 and OGG1 in base excision repair (BER), XPA and MMS19 in nucleotide excision repair (NER) and RPA4 in mismatch repair (MMR). XRCC4 and MSH4 overexpression and PRKDC down-regulation were significant changes among genes associated exclusively with double strand break (DSB) repair. Differences in genes coding for multifunctional proteins, involved in both SSB and DSB, and/or common damage checkpoints were also observed. These included down-regulation of PARP1, PNKP, LIG1, POLE, MSH2, MDC1, FANCD2, BLM, BAP1, POLH and MUS81; and up-regulation of ERCC1, TDP1 and POLK.
We next investigated whether genes exclusively involved in DNA damage checkpoints were altered in CMML patients. We found relative underexpression of two SSB sensors, ATRIP and RAD9A; two common mediators/effectors, MDC1 and CDC25B; and one cell cycle promoter, CDK2. Two potent cyclin-dependent kinase inhibitors, CDKN1A (otherwise known as p21) and CDKN1C, demonstrated 5-and 2-fold increased expression, respectively, compared with healthy individuals.
Targetable DNA repair differentially expressed genes: validation and behaviour through the myeloid spectrum
We selected four of the 30 RNA-Seq DEGs for validation in CMML CD34
+ BM selected cells, in an independent CMML cohort and further characterization through the spectrum of myeloid neoplasms. Candidate genes for validation were selected on clinical grounds, specifically targeting those predicted to have the highest translational potential. Categories selected were: (i) druggable oncogenes found to be highly overexpressed, allowing for modulation of a specific DNA repair pathway (CDKN1A, ERCC1); (ii) oncogenes underexpressed but with inhibitory molecules already being tested in cancer (PARP1), (Zereshkian et al, 2014; Muvarak et al, 2016) and (iii) genes down-regulated and with a previously documented association with CMML pathogenesis (BAP1) (Dey et al, 2012) . The CMML validation cohort included 74 patients (Table I ). Gene expression levels for the 4 validation genes were quantified by RT-qPCR and compared with expression data from 9 healthy bone marrow donors. Corroborating the findings from our discovery cohort, we observed statistically significant and direction-concordant dysregulation for all four of the shortlisted genes (CDKN1A, ERCC1, PARP1, BAP1) in the independent RT-qPCR CMML validation cohort (Fig 1 and Table SV ): CDKN1A showed a 3 log fold change (logFC) overexpression compared with controls (P = 0Á01), and we validated ERCC1 to be up-regulated in patients (1Á8 logFC versus controls, P < 0Á001); PARP1 and BAP1 were confirmed to be down-regulated when comparing the validation CMML cohort versus controls (PARP1 À0Á5 logFC, P = 0Á047); BAP1 À0Á6 logFC, P = 0Á008).
It could be hypothesized that the distinct expression in CMML BM cells of our candidate genes could be a feature that distinguishes the monocytic compartment, either healthy or leukaemic, and that the differences found herein are due Table I . Characteristics at baseline of CMML patients included in the RNA-Seq cohort (n = 27) and in the extended validation cohort (n = 74).
Variable
RNA-Seq discovery cohort (n = 27) Extended validation cohort (n = 74) (Table SVI) . The RT-qPCR expression analysis for PARP1, CDKN1A, ERCC1 and BAP1 was then extended to our own series of MDS (n = 70), AML (n = 53) and CML (n = 25) patients (Fig 1 and Table SV) . Similar to CMML, ERCC1 was uniformly up-regulated in every entity tested, whilst CDKN1A was markedly overexpressed in each disorder with the exception of CML. Interestingly, PARP1 and BAP1 displayed opposite directions of dysregulation in CMML and CML cases (underexpressed) versus MDS and AML (overexpressed). Microarray Innovations in LEukaemia MILE study microarray data reproduced the direction of misregulation of PARP1, CDKN1A, ERCC1 and BAP1 in every disease subset tested (Haferlach et al, 2010) .
CD34
+ cells PARP1, CDKN1A, ERCC1 and BAP1 in CMML, MDS and donors Total RNA was extracted from CD34 + BM cells selected (with a median average purity of 95%) from 15 CMML patients (from the RNA-Seq discovery cohort), 15 MDS cases and 15 healthy donors, and studied by RT-qPCR ( Figure S2 ). Compared with BM CD34 + from controls, we confirmed the upregulation of CDKN1A in CMML CD34 + (1Á5 logFC, P = 0Á03), ERCC1 (0Á3 logFC, P = 0Á04) and the downregulation of PARP1(À0Á6 logFC, P = 0Á02) and BAP1 (À0Á3 logFC, P = 0Á04). Pyrosequencing was used to confirm the unmethylated status of our main candidates for a synthetic lethality approach: the overexpressed double-break fidelity genes ERCC1 and CDKN1A. Lack of methylation of their promoter CpGs would add rationale for incorporating a different modulation if these genes to currently used hypomethylating agents. Our design covered two regions in the CDKN1A promoter (including 5 CpGs) and one region in the ERCC1 promoter (including 3 CpGs). In agreement with the microarray data, all CpGs probed by this method were found to be unmethylated, both in bone marrow samples from 56 CMML cases and 16 controls (Table SVIII) .
Therefore, promoter methylation does not appear to be a mechanism by which DNA repair genes are differentially expressed in CMML versus healthy BM. Consistent with this, patients treated with the hypomethylating agent azacitidine for 3 cycles failed to show any significant correction of the aberrant expression across any of the identified DNA Repair DEGs (Fig 2) . This was the case for both clinical responders (n = 2) and non-responders (n = 3).
Mutational correlates for CMML DNA Repair DEGs
We next investigated whether DNA Repair DEGs in CMML were associated with particular patterns of recurrent mutations. We perfomed targeted amplicon sequencing using a panel of 18 genes known to be recurrently mutated in CMML in 57 samples with available DNA from the CMML validation cohort. A total of 147 non-synonymous somatic variants were identified ( Figure S3 and Table SIX), including typical CMML-associated mutations and frequencies: TET2 (total number of mutations = 82, 77% cases mutated), SRSF2 (n = 15, 26%), and ASXL1 (n = 9, 16%), Next, we compared expression of the shortlisted CMML DEGs, CDKN1A, ERCC1, PARP1 and BAP1, across patient groups displaying mutations in TET2, in a splicing factor (SRSF2, SF3B1, ZRSR2), or in a chromatin regulator (ASXL1, EZH2). We found significantly decreased expression of PARP1 in TET2-mutated cases (À0Á69 logFC, P = 0Á02), and of both CDKN1A (À2Á5 logFC, P = 0Á01) and BAP1 (À0Á2 logFC, P = 0Á04) in chromatin regulator-mutated cases. Presence of a splicing factor mutation was not associated with specific expression patterns for the observed CMML DNA repair DEGs (data not shown).
SRSF2 mutations induce widespread aberrant splicing events in DNA repair genes in CMML Given that mutations in specific spliceosome components have distinct impacts on splicing and that SRSF2 mutations are by far the most common such mutations in CMML, (Meggendorfer et al, 2012) we focused our analysis on CMML patients harbouring typical SRSF2 proline 95 mutations (n = 7). Compared with patients with no mutations in any of the spliceosomal genes included in our panel (n = 13), at least one significant aberrant splicing event (inclusion ≥0Á05; false discovery rate <0Á05) was observed for 48 of the 204 DNA repair genes considered in this study (Fig 3  and Tables SX-XIV) . Exon skipping/cassette exon events were most common, occurring in 42 genes; many of these displayed events involving multiple exons. Other significant events included mutually exclusive exons (n = 16 genes), alternative 3 0 splice site (n = 8), alternative 5 0 splice site (n = 1) and retained intron (n = 1).
Only a small minority of aberrant splicing events occurred in CMML DEGs: skipped exons in MDC1, POLK and TDP1; mutually exclusive exons in MDC1 and POLK; and alternative 3 0 splice sites in POLH and XRCC4. Thus, significant aberrant splicing events with potential to influence downstream function were found in an additional 43 DNA repair genes, beyond those demonstrating misregulated expression levels in CMML.
Clinico-biological correlates for CMML DNA Repair DEGs
Next, we investigated associations of the DNA repair DEGs with various clinical parameters in our validation cohort of 74 CMML patients (Table SXV) . To this regard, cases with CDKN1A overexpression were characterized by fewer cytogenetic anomalies (P = 0Á033). It was previously described that PARP1 is required for the generation of chromosomal translocations (Wray et al, 2013) . As expected from its down-regulation, only one of 101 CMML patients across our discovery and validation cohorts presented with such a balanced translocation; this case was atypical in our cohort in displaying up-regulation of PARP1 compared to controls. Extending analysis to our MDS and AML patients, PARP1 expression was significantly higher in patients with (n = 14) versus without (n = 97) a translocation (P = 0Á03; Tables SXVI and SXVII). AML patients who failed to achieve complete remission (CR) after induction chemotherapy displayed markedly higher expression of CDKNA1 (22-fold change versus 11-fold change; P = 0Á02) and ERCC1 (25-fold change versus 14-fold change; 
Further insight into DNA repair transcriptome among myeloid disorders: comparison with the MILE study
We were interested to compare how the transcriptional changes identified in our CMML cohort compared with those in related myeloid disorders. We therefore compared our unbiased RNA-Seq data with results extracted from the MILE study (Mills et al, 2009; Haferlach et al, 2010) , which compared gene expression by microarray on unfractionated bone marrow from patients with a variety of leukaemias versus healthy donors. Accordingly, transcriptional data for DNA repair components were extracted from a large dataset of 206 MDS, 351 normal karyotype AML (nkAML) and 48 complex karyotype AML (ckAML; defined by the occurrence of at least three clonal chromosomal abnormalities) patients, and compared gene expression patterns versus 73 healthy donors. Surprisingly, MDS samples from the MILE study demonstrated predominant up-regulation of DNA repair genes, with 14 of 20 misregulated targets up-regulated versus healthy donors ( Figure S4 and Table SXVIII) . By contrast, ckAML showed a global defect with predominance of down-regulated DNA repair components (37 of 50 misregulated targets) (Fig 1 lower panel and Table SXIX) .
Overlay of significant expression patterns from our CMML dataset with MILE cohorts of MDS and ckAML patients revealed three shared genes misregulated in the same direction across all three cohorts: overexpression of ERCC1, and down-regulation of NEIL1 and CDC25B ( Figure S5 ).
Of note, several genes displayed antithetic misregulation depending on the underlying disease: BAP1 was up-regulated in ckAML and down-regulated in CMML; whereas CDK1 and EXO1 were up-regulated in MDS with the opposite effect observed among ckAML cases. These findings suggest intriguing differences in pathogenic role for DNA repair transcriptional defects between these related but distinct clinicopathological entities.
Discussion
Differences in chromosomal and gene-level DNA lesions across the spectrum of myeloid neoplasms can result from diversity of the underlying DNA repair defects, pointing toward the existence of disorder-specific targets in this machinery. In this study, we identified distinct targetable and misregulated DNA repair genes in a deep RNA-Sequenced discovery cohort of CMML patients. Notably, the broad pattern differs from that extracted from previously published MDS and AML cases. We validated our identified candidates in BM CD34 + CMML cells, in a large and independent series of CMML patients, and compared their behaviour through different myeloid disorders by means of a direct RT-qPCR technique. Beyond simple transcriptional expression changes, we observed a host of additional novel splicing abnormalities in CMML patients bearing mutations in the spliceosome component SRSF2. Independently from its cell cycle checkpoint function, CDKN1A has been shown to regulate the accuracy of replication-coupled DSB repair and the maintenance of chromosome stability (Patel et al, 2017) . Our results indicate a Box plots indicating significant exon skipping events for 42 DNA repair genes, comparing average exon usage for SRSF2-mutated (n = 7; grey boxes) versus spliceosome mutation wild type (WT, n = 14; white boxes) chronic myelomonocytic leukaemia (CMML) cases from our validation cohort RNA-Seq dataset. Exon skipping events were considered significant if occurring with inclusion difference level ≥0Á05 and false discovery rate <0Á05. Where multiple skipped exon events occurred in the same gene, only the event displaying greatest magnitude of difference was included. Boxes represent the interquartile range, with median inclusion level indicated by the bold bar; whiskers and outliers are plotted using the Tukey method. (B) Volcano plot indicating all significant exon skipping events comparing SRSF2-mutated versus spliceosome mutation wild type CMML cases. Events involving DNA repair genes are highlighted in deep grey; selected significant events are labelled. (C) and (D) Sashimi plots comparing RNA-Seq reads across splice junctions for two illustrative patients, for two exemplar alternative splicing events: (C) exon skipping event in POLK and (D) intron retention event in POLM. SRSF2-mutated patients are indicated by grey tracks; spliceosome mutation wild type patients are represented by black tracks. Relevant genomic coordinates and intron/exon tracks are provided beneath each plot.
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ª 2018 British Society for Haematology and John Wiley & Sons Ltd striking up-regulation of this gene in CMML patients, although not specific to this entity given that it is replicated across the spectrum of myeloid neoplasms. This overexpression did not correlate with presence of disrupted TP53, the main CDKN1A mediator, (Brugarolas et al, 1995) either by mutation or misregulation. Thus, targeting this DSB fidelity gene by its TP53-independent activity in cells with a relatively preserved DSB repair pathway emerges as an exciting and plausible synthetic lethality approach in CMML and other myeloid cancers. ERCC1, initially placed among the NER components, has ubiquitous roles in the DNA damage response. Its defects produced unexpected deleterious and complex DNA lesions (McWhir et al, 1993) . Subsequently, an increased sensitivity to interstrand cross link (ICL)-inducing agents, and a key role in deleting non-homologous tails at rupture bounds before they are rejoined, established a predominant role in the DSB repair machinery (Kim et al, 2011; Ahmad et al, 2008) . In our study, ERCC1 gene dosage was significantly increased in CMML and MDS patients compared with controls, and to a still greater degree (doubled) in AML. Interestingly, as for CDKN1A, overexpression of ERCC1 in AML patients was significantly associated with failure to achieve complete remission after induction chemotherapy.
Focal DNA hypermethylation in the context of broad hypomethylation is a hallmark of myeloid neoplasms, but this dysregulation is not homogeneous through the ambit of these diseases (Figueroa et al, 2010; Itzykson & Fenaux, 2014) . In our CMML cohort, with the exception of MSH4, all promoter CpGs for all shortlisted DEGs extracted showed un unmethylated status. Moreover, we noted no significant reversal of gene expression changes after 3 cycles of azacitidine in a limited series of CMML patients, irrespective of their clinical response to treatment. This finding supports that DEGs in the DNA repair pathway are not directly subordinated to this epigenetic control mechanism and recasts their modulation as a suitable candidate for combination therapy alongside hypomethylating agents. Indeed, we directly confirmed in our cohort the demethylated status of ERCC1 and CDKN1A promoters.
It was recently shown that alternative NHEJ (aNHEJ) elements are required for formation of chromosomal translocations (Zhang & Jasin, 2011) . PARP1, the initiator of aNHEJ, is a key player in the molecular mechanism underlying this process, and its inhibition or repression markedly decreases or completely abrogates translocations, respectively (Wray et al, 2013) . Our findings fully support these basic observations: the direction of PARP1 misregulation was inverted in MDS and AML patients (upregulated; translocations present in a significant proportion of cases), compared with our CMML cohort (downregulated; translocations absent). The disease-specific differences in direction of misregulation may partially explain the different distributions of genomic lesions observed, but also underpins the need for neoplasm-personalized therapeutic modulation. Recent work has founded an in vitro biological rationale for combining PARP1 and demethylating agents in myeloid disease (Muvarak et al, 2016) . Our study indicates that responses may be heterogeneous across the myeloid spectrum, potentially less effective in CMML than described in MDS and AML models (Gaymes et al, 2009) .
We detected and validated a significant underexpression of BAP1 in CMML samples, shared only by CML patients among the myeloid diseases studied. This deubiquinase is mutated in various hereditary cancers and its deletion is associated with the appearance of myelodysplastic/myeloproliferative features in mice (Dey et al, 2012) . BAP1 function is intimately linked with that of ASXL1, commonly mutated in CMML, and it was recently shown that the interaction between ASXL1 and BAP1 was restored in ASXL1-mutation corrected clones (Valletta et al, 2015) . Accordingly, our ASXL1-mutated CMML cases were characterized by a reduced BAP1 gene dosage, that reached statistical significance when combined with cases bearing mutations in EZH2, another chromatin modulator. In addition, the reduction of BAP1 transcripts in CML patients we identified replicates findings recently reported (Dkhissi et al, 2015) . Although the granulomonocytic compartment represented a median average of 82% of cells in the unfractionated bone marrow samples used in our CMML RNA-seq discovery cohort, it could be argued the abnormal repartition of cell lineages could be responsible of the changes detected. We show here that the alterations detected in the RNA-seq experiment were also validated in bone marrow CD34 + cells from CMML and healthy donors. Mutations in splicing factors are common within myeloid malignancies, but their role in pathogenesis has not been extensively delineated (Yoshida et al, 2011) . Recent data show how mutant SRSF2, frequently mutated in CMML, promotes mis-splicing and degradation of EZH2 in mice and cell lines (Kim et al, 2015) . When comparing SRSF2 mutated versus non mutated cases, only a minority of aberrant splicing events occurred in CMML DEGs, none in ERCC1, CDKN1A, PARP1 and BAP1. Regarding non DEGs, three components of the SSB pathways, EXO1, ENDOV and ERCC6 showed the highest rate of exon skipping (beyond À0Á3) in mutant cases, pointing out the preference for defects in single strand repair mechanisms in CMML.
We uncovered different patterns of DNA repair gene misregulation when comparing our CMML cohort with the MDS and ckAML subsets of the MILE study. Perhaps unsurprisingly, a global disruption to all DNA repair pathways was observed in ckAML, with a remarkably damaged homologous recombination pathway. Conversely, we did not expect upregulation to be a hallmark of MDS, the prototypical "hypermethylation" disease.
In summary, we have identified, by means of an unbiased high-throughput approach, and validated in BM CD34 + CMML cells and in an independent cohort, a subset of DNA repair genes consistently misregulated in CMML. We highlight meaningful clinical and mutational correlates, alongside A. M. Hurtado et al relationships that point towards their compensatory nature within a damaged cancer DNA repair machinery. The genes identified warrant further study as potential novel therapeutic targets, both directly and through modulation of associated compensatory pathways. In particular, CDKN1A and ERCC1 emerge as realistic candidates for a synthetic lethality approach. Indeed, we further identified important diseasespecific differences for DNA repair DEGs comparing different myeloid malignancies, with potential translational ramifications for the positioning of novel therapeutic strategies. For example, our findings suggest that the promise of PARP1 inhibition appears less pertinent to CMML than for other myeloid diseases. These differences might also partially explain the different genomic and phenotypic manifestations of different myeloid neoplasms and shed insights into their distinctive biology.
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